Reviewer's report

Title: Simultaneous Identification of 36 mutations in KRAS codons 61 and 146, BRAF, NRAS, and PIK3CA in a Single Reaction by Multiplex Assay Kit

Version: 3 Date: 19 June 2013

Reviewer: Taroh Satoh

Reviewer's report:

Major Compulsory Revisions
Concordance of Multiplex assay kit and direct sequence is impressive and really has clinical value. But there are two points which should be discussed.
1. With cetuximab treatment KRASG13D mutations appear to be different from codon 12 mutations. Clinical efficacy for patients with this mutation should be analyzed separately.
2. BRAF mutation is considered not predictive but prognostic, clinical efficacy for this mutation should be described separately.

I understand numbers of these patients are not sufficient to draw any conclusions but readers are eager to know.

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:
'I declare that I have no competing interests.